Merganser Biotech

Merganser Biotech is a privately held, preclinical stage biotechnology company focused on the evaluation of novel hepcidin mimetic peptides for the treatment of beta thalassemia and other rare hematological and iron overload diseases. The company has an exclusive worldwide license to patent rights for this technology initially developed at UCLA.

<< Portfolio